Tuesday, February 27, 2024
HomeUncategorizedPeptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in...

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

Friday, 28 July 2023, 06:00 HKT/SGT
    
Source: Peptomyc SL
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
OMO-103 in Phase 1b clinical trial

BARCELONA, July 28, 2023 – (ACN Newswire) – Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc’s clinical development, regulatory and medical affairs activities, says: “I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field”.

This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d’Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Munoz at the Hospital Gregorio Maranon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies – founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

Contact Information
Laura Soucek
CEO
[email protected]
+34695207869


Topic: Press release summary


Source: Peptomyc SL

Sectors: BioTech, Healthcare & Pharm

http://www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Latest Press Releases


DENSO Announces First Quarter Financial Results
  

Friday, July 28, 2023 2:51:00 PM


MHI to Issue The Second Series of Transition Bonds
  

Friday, July 28, 2023 2:02:00 PM


Huatai Securities Initiates Coverage of CIMC Group with “Overweight” Rating, Citing Recovery in Offshore Drilling Demand
  

July 28, 2023 12:10 HKT/SGT


Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
  

July 28, 2023 06:00 HKT/SGT


GMG Appoints Nu-Calgon as THERMAL-XR(R) Distributor for North America
  

July 27, 2023 20:16 HKT/SGT


GMG Appoints Nu-Calgon as THERMAL-XR(R) Distributor for North America
  

July 27, 2023 20:09 HKT/SGT


Digital Business Card Company Mobilo Secures $4.1M in Seed Funding
  

July 27, 2023 20:00 HKT/SGT


Rekor Systems Announces Nomination of Professor Sanjay Sarma and Tim Davenport As New Board Directors
  

July 27, 2023 19:30 HKT/SGT


Honda: Seven Automakers Unite to Create a Leading High-Powered Charging Network Across North America
  

Thursday, July 27, 2023 5:55:00 PM


Hitachi Payment Services to Acquire Writer Corporation’s Cash Management Business
  

Thursday, July 27, 2023 4:55:00 PM


More Press release >>

 Events:
More >>

Copyright © 2023 ACN Newswire – Asia Corporate News Network
Connect With us: 
 
 
 

Read More

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments